TABLE 3.

Acne vulgaris management guidelines: Summary of publications including recommendations on use of isotretinoin

SOURCE	PUBLICATION	COMMENTS
GENERAL POPULATION (Teenagers, Adults)
European Evidence-Based Guidelines for Treatment of Acne81	Journal of the European Academy of Dermatology and Venereology (2012)	Not recommended for comedonal acne. Not generally recommended for non-nodular inflammatory (papulopustular) acne
Guidelines of Care: Acne Vulgaris Management (American Academy of Dermatology)75	Journal of the American Academy of Dermatology (2007)	Unanimous agreement that ISO is also useful for lesser degrees of acne that resist treatment or produce physical or psychological scarring
Acne Guidelines (Global Alliance to Improve Outcomes in Acne)82	South African Medical Journal (2005)	Recognized as most effective anti-acne treatment, but should be reserved for severe cases, moderate but unresponsive cases, and acne with psychological distress
Consensus on Evidence- Based Practice in Acne (Asian Working Group)83	The Journal of Dermatology (2011)	Recommended as primary therapy for severe acne and second-tier treatment for moderate acne that is poorly responsive to other treatments; suggests a target cumulative dose of 120–150mg/kg be reached over the treatment course
PEDIATRIC POPULATION
Evidence-Based Recommendations for Pediatric Acne (American Acne and Rosacea Society and American Academy of Pediatrics)84	Pediatrics (2013)	Recommended starting dose of 0.5mg/kg/day for the first 4 weeks, increasing to 1mg/kg/day. Recommended uses include severe nodular acne, acne with scarring, and/or refractory inflammatory acne. Extensive counseling suggested, particularly with respect to pregnancy prevention in girls.